Literature DB >> 8566091

Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.

K Tsou1, S L Patrick, J M Walker.   

Abstract

Tolerance to delta 9-tetrahydrocannabinol (delta 9-THC) was produced in rats by twice daily injections (15 mg/kg i.p.) for 6.5 days. Administration of the cannabinoid antagonist SR141716A (i.p. or i.c.v.) induced a profound precipitated withdrawal syndrome in delta 9-THC-tolerant animals. The syndrome was characterized by a disorganized pattern of constantly changing brief sequences of motor behavior. Autonomic signs were not evident. THC-tolerant animals that were treated with vehicle remained quiet throughout the observation period.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8566091     DOI: 10.1016/0014-2999(95)00360-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  35 in total

1.  Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice.

Authors:  Anna Castañé; Rafael Maldonado; Olga Valverde
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

2.  Precipitated Δ9-THC withdrawal reduces motivation for sucrose reinforcement in mice.

Authors:  M L Eckard; K R Trexler; B T Kotson; K G Anderson; S G Kinsey
Journal:  Pharmacol Biochem Behav       Date:  2020-06-09       Impact factor: 3.533

3.  Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips.

Authors:  Fabio Guagnini; Paola Cogliati; Sylvain Mukenge; Gianfranco Ferla; Tiziano Croci
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

4.  Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Authors:  Liting Deng; Josée Guindon; Benjamin L Cornett; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2014-04-25       Impact factor: 13.382

5.  CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Authors:  Liting Deng; Benjamin L Cornett; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

Review 6.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

7.  Evaluation of sex differences in cannabinoid dependence.

Authors:  Julie A Marusich; Timothy W Lefever; Kateland R Antonazzo; Rebecca M Craft; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2014-02-12       Impact factor: 4.492

Review 8.  Marijuana dependence: not just smoke and mirrors.

Authors:  Divya Ramesh; Joel E Schlosburg; Jason M Wiebelhaus; Aron H Lichtman
Journal:  ILAR J       Date:  2011

9.  Mesolimbic dopaminergic decline after cannabinoid withdrawal.

Authors:  M Diana; M Melis; A L Muntoni; G L Gessa
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.